PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19910577-6 2010 Blockade of the AT1 receptor by valsartan or losartan for 2 weeks restored the myocardial response of OLETF rats to erythropoietin-induced infarct size limitation (39.4+/-4.9% and 31.2+/-7.5). Valsartan 32-41 angiotensin II receptor, type 1a Rattus norvegicus 16-19 17082724-6 2006 METHODS: SHRSP and Wistar-Kyoto (WKY) rats were treated with the AT1R blocker valsartan for 14 days. Valsartan 78-87 angiotensin II receptor, type 1a Rattus norvegicus 65-69 19080339-13 2008 Valsartan decreased the level of AGTR1 in repeatedly OVA-challenged rats. Valsartan 0-9 angiotensin II receptor, type 1a Rattus norvegicus 33-38 19080339-19 2008 Valsartan, a AGTR1 antagonist, could inhibit AGTR1 expression and partially inhibits structural airway changes as well as airway inflammation in chronic OVA-exposed rats. Valsartan 0-9 angiotensin II receptor, type 1a Rattus norvegicus 13-18 19080339-19 2008 Valsartan, a AGTR1 antagonist, could inhibit AGTR1 expression and partially inhibits structural airway changes as well as airway inflammation in chronic OVA-exposed rats. Valsartan 0-9 angiotensin II receptor, type 1a Rattus norvegicus 45-50 17318789-6 2006 METHODS: This study was conducted on control non-treated rats (n=13), methionine-treated rats (1.5 mg/kg/day, n=18) and methionine plus oral AT1 antagonist (valsartan, 30 mg/kg/day, n=13) treated rats for 56 days. Valsartan 157-166 angiotensin II receptor, type 1a Rattus norvegicus 141-144 18822915-8 2008 (3) The mRNA and protein expressions of AT1 receptor were obviously lower in the three treated groups than those in the model groups (P < 0.05); but the lowering was more significant in the valsartan treated group (P < 0.05). Valsartan 193-202 angiotensin II receptor, type 1a Rattus norvegicus 40-43 17644087-11 2007 Selective angiotensin AT1 receptor blocker valsartan (10(-4) M) or candesartan (10(-7) M) abolished aldosterone-induced vasoconstriction. Valsartan 43-52 angiotensin II receptor, type 1a Rattus norvegicus 22-25 16043663-5 2005 The angiotensin II effect was reversed by AT1 receptor blocker valsartan. Valsartan 63-72 angiotensin II receptor, type 1a Rattus norvegicus 42-45 11725169-2 2001 OBJECTIVE: To compare the inhibitory potency of candesartan, valsartan, eprosartan and embusartan in blocking presynaptically and postsynaptically located AT1 receptors. Valsartan 61-70 angiotensin II receptor, type 1a Rattus norvegicus 155-158 15539634-8 2004 This effect was AT1 receptor mediated, because AT1 receptor antagonists valsartan, candesartan, and losartan inhibited Ang II-induced endoglin expression, whereas the AT2 receptor antagonist PD123319 had no effect. Valsartan 72-81 angiotensin II receptor, type 1a Rattus norvegicus 16-19 15539634-8 2004 This effect was AT1 receptor mediated, because AT1 receptor antagonists valsartan, candesartan, and losartan inhibited Ang II-induced endoglin expression, whereas the AT2 receptor antagonist PD123319 had no effect. Valsartan 72-81 angiotensin II receptor, type 1a Rattus norvegicus 47-50 15302895-10 2004 In SHRSP, blockade of AT1 receptor with valsartan prevents the development of proteinuria, delays the appearance of brain damage, preserves renal structure, and increases survival under stressful conditions. Valsartan 40-49 angiotensin II receptor, type 1a Rattus norvegicus 22-25 15501693-7 2004 Ang II induced contractile response was blocked by valsartan (100 microM, selective AT1 receptor antagonist) but not PD 123,319 (100 microM, selective and potent AT2 receptor antagonist). Valsartan 51-60 angiotensin II receptor, type 1a Rattus norvegicus 84-87 14966778-7 2004 CONCLUSIONS: AT(1)R blockade with valsartan induces short-term cardioprotection associated with enhanced AT(2)R expression in both dog and rat models of in vivo RMI. Valsartan 34-43 angiotensin II receptor, type 1a Rattus norvegicus 13-19 12623990-3 2003 Rats were anesthetized with alpha-chloralose, and the effects of microinjecting the AT1R antagonist valsartan (Val) or angiotensin II (Ang II) into the RVLM on MAP were measured. Valsartan 100-109 angiotensin II receptor, type 1a Rattus norvegicus 84-88 12364362-3 2002 Injection of the nonpeptide AT1 receptor antagonist valsartan bilaterally into the rostral ventrolateral medulla of choralose-anesthetized adult spontaneously hypertensive rats produced a dose-related decrease in mean arterial pressure, with a maximal effect of approximately 30 mm Hg. Valsartan 52-61 angiotensin II receptor, type 1a Rattus norvegicus 28-31 12023686-12 2002 CONCLUSION: The results indicate that AT1-receptor blockade with valsartan influences AT2-receptor-mediated angiotensin II responses to a greater extent than with losartan, as quantified by renal interstitial fluid cGMP. Valsartan 65-74 angiotensin II receptor, type 1a Rattus norvegicus 38-41 34075552-1 2022 Sacubitril/valsartan (SAC/VAL) prevents angiotensin II (AngII) from binding AT1-R and blocks degradation of natriuretic peptides. Valsartan 11-20 angiotensin II receptor, type 1a Rattus norvegicus 76-81 9150473-6 1997 Administration of the ACE inhibitor ramipril and the AT1 receptor blocker valsartan blunted the increase in TGF-beta 1 mRNA, and attenuated the structural and functional manifestations of injury. Valsartan 74-83 angiotensin II receptor, type 1a Rattus norvegicus 53-56 11433183-8 2001 In contrast, all the three AT1 receptor antagonists exerted a similar thrombolytic action and comparably decreased the thrombus weight in the therapeutic and preventive model of venous thrombosis, although in the latter case a high dose of losartan was slightly more effective than a corresponding dose of EXP3174 and valsartan. Valsartan 318-327 angiotensin II receptor, type 1a Rattus norvegicus 27-30 11115077-9 2000 The administration of the AT2R antagonist PD123319 or the AT1R antagonist valsartan was associated with attenuation of the increases in both PCNA- and TUNEL-positive cells following Ang II infusion. Valsartan 74-83 angiotensin II receptor, type 1a Rattus norvegicus 58-62 10818067-7 2000 These data demonstrate that AT(1)R blockade with valsartan is associated with release of renal BK, which in turn mediates NO production. Valsartan 49-58 angiotensin II receptor, type 1a Rattus norvegicus 28-34 9374809-3 1997 Blockade of AT1 receptors with valsartan increased slightly sodium and water excretion at low renal perfusion pressure (RPP). Valsartan 31-40 angiotensin II receptor, type 1a Rattus norvegicus 12-15 30288456-3 2018 A new 18F-labeled PET tracer derived from the clinically used AT1 antagonist valsartan showing the least possible chemical alteration from the valsartan structure has been designed and synthesized with several strategies, which can be applied for the syntheses of further derivatives. Valsartan 77-86 angiotensin II receptor, type 1a Rattus norvegicus 62-65 32688140-9 2020 The increased Netrin-1 expression was decreased by valsartan to block AT1R. Valsartan 51-60 angiotensin II receptor, type 1a Rattus norvegicus 70-74 30554582-12 2018 Compared to normal group and Val group, AT1R expression was significantly up-regulated in AL group, without significant difference between diabetes group and AL group. Valsartan 29-32 angiotensin II receptor, type 1a Rattus norvegicus 40-44 30288456-3 2018 A new 18F-labeled PET tracer derived from the clinically used AT1 antagonist valsartan showing the least possible chemical alteration from the valsartan structure has been designed and synthesized with several strategies, which can be applied for the syntheses of further derivatives. Valsartan 143-152 angiotensin II receptor, type 1a Rattus norvegicus 62-65 30288456-6 2018 A fast and clear kidney uptake could be observed, and this renal uptake could be selectively blocked by pretreatment with AT1-selective antagonist valsartan. Valsartan 147-156 angiotensin II receptor, type 1a Rattus norvegicus 122-125 26137805-5 2015 Concurrently, myocardial AT1 and AT2 receptor mRNA and protein expression were increased with valsartan. Valsartan 94-103 angiotensin II receptor, type 1a Rattus norvegicus 25-28 26709040-5 2016 Valsartan (VAL; 10mg/kg), a selective AT1 receptor antagonist, was administered in a single bolus injection before ALDO infusion. Valsartan 0-9 angiotensin II receptor, type 1a Rattus norvegicus 38-41 26709040-10 2016 RESULTS: AT1 blockade with valsartan significantly reduced ALDO-induced thrombosis expressed as a reduced thrombus mass (p<0.05 vs ALDO) and diminished the incidence of thrombosis. Valsartan 27-36 angiotensin II receptor, type 1a Rattus norvegicus 9-12 29620193-10 2018 In vitro, pre-treatment with Ac-SDKP or valsartan attenuated the expression of alpha-SMA, Col I, Fn and AT1 in Ang II-induced fibroblasts. Valsartan 40-49 angiotensin II receptor, type 1a Rattus norvegicus 104-107 24340072-4 2013 Preconditioning of BMMNCs via AT2R stimulation directly with an AT2R agonist CGP42112A or indirectly with angiotensin II plus AT1R antagonist valsartan led to ERK activation and increased eNOS expression as well as subsequent nitric oxide generation, ultimately improved cardiomyocyte protection in vitro as measured by co-culture approach. Valsartan 142-151 angiotensin II receptor, type 1a Rattus norvegicus 126-130 25350112-9 2014 Hcy time-dependently induced collagen type 1 and AT1R expression, with the highest induction observed at 48 h. Also, we observed that the AT1R blocker, valsartan, attenuated collagen type 1 and AT1R expression. Valsartan 152-161 angiotensin II receptor, type 1a Rattus norvegicus 49-53 25350112-9 2014 Hcy time-dependently induced collagen type 1 and AT1R expression, with the highest induction observed at 48 h. Also, we observed that the AT1R blocker, valsartan, attenuated collagen type 1 and AT1R expression. Valsartan 152-161 angiotensin II receptor, type 1a Rattus norvegicus 138-142 25350112-9 2014 Hcy time-dependently induced collagen type 1 and AT1R expression, with the highest induction observed at 48 h. Also, we observed that the AT1R blocker, valsartan, attenuated collagen type 1 and AT1R expression. Valsartan 152-161 angiotensin II receptor, type 1a Rattus norvegicus 138-142 25014676-10 2014 Additionally, pretreatment with valsartan significantly reduced Ang II levels, AT1 receptor, and p38 mitogen-activated protein kinase (MAPK) expression. Valsartan 32-41 angiotensin II receptor, type 1a Rattus norvegicus 79-82 23499691-4 2013 In the present study, we examined whether inhibition of RAS with Valsartan, an Angiotensin II 1 receptor (AT1) antagonist, could reduce apoptosis during reperfusion. Valsartan 65-74 angiotensin II receptor, type 1a Rattus norvegicus 79-104 23499691-4 2013 In the present study, we examined whether inhibition of RAS with Valsartan, an Angiotensin II 1 receptor (AT1) antagonist, could reduce apoptosis during reperfusion. Valsartan 65-74 angiotensin II receptor, type 1a Rattus norvegicus 106-109 23414835-1 2013 We previously reported that the AT1 receptor antagonist valsartan and the angiotensin converting enzyme (ACE) inhibitor enalapril decrease DNA synthesis and stimulate apoptosis in interstitial fibroblasts and epicardial mesothelial cells during regression of ventricular hypertrophy in spontaneously hypertensive rats (SHR). Valsartan 56-65 angiotensin II receptor, type 1a Rattus norvegicus 32-35